Foundayo under the Medicare GLP-1 Bridge
Short answer: Foundayo is the third medication covered at $50/month under the Medicare GLP-1 Bridge, alongside Wegovy and Zepbound (KwikPen). Coverage mechanics are identical: provider-submitted prior authorization, then $50 monthly fills at a participating pharmacy.
Program facts last verified against CMS: July 21, 2026
What we can tell you today
Foundayo is the newest of the three covered products, and public prescribing experience with it is thinner than with Wegovy and Zepbound — so we're deliberately not filling this page with secondhand detail. What's certain from CMS's program terms: it's covered at the same flat $50, under the same eligibility tiers and prior-authorization process, nationwide.
Whether Foundayo is the right choice among the three is exactly the conversation to have with your prescriber, who has access to current labeling and clinical data. We'll expand this page as reliable public information accumulates — it carries the same 'last verified' dating as everything else on this site.
Take the 2-minute eligibility check →
Common questions
Is Foundayo covered on the same terms as Wegovy and Zepbound?
Yes — same $50 monthly copay, same eligibility tiers, same prior-authorization process through the program's central processor.
Which of the three drugs should I ask for?
That's a prescriber decision based on your history and current clinical data. All three cost the same $50 under the program, so cost doesn't have to drive the choice.
Are there form restrictions like Zepbound's KwikPen rule?
The KwikPen restriction is specific to Zepbound. Confirm current dispensing specifics for Foundayo with your pharmacist at the first fill.
Related
Program-fact sources: CMS — Medicare GLP-1 Bridge · KFF